SCHEMBL20239182

SCHEMBL20239182

CCc1cnc(NCc2cc(Oc3ccc(CS(=O)(=O)NC)cc3)nc(C)n2)nc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT2 Q96PD7 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.36
RAB9A P51151 2/20 0.36
NPC1 O15118 1/20 0.36
MAPT P10636 3/20 0.33
HPGD P15428 1/20 0.33
LMNA P02545 3/20 0.33
HTT P42858 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
ALDH1A1 P00352 2/20 0.32
GLA P06280 1/20 0.32
GRIN1 Q05586 5/20 0.32
GRIN2B Q13224 5/20 0.32
RORC P51449 1/20 0.31
RXRA P19793 3/20 0.31
PGR P06401 1/20 0.31
VNN1 O95497 1/20 0.30
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16738674 0.90 DGAT2 (0.57) DGAT2SMN1; SMN2RAB9AMAPTLMNA
SCHEMBL20239140 0.89 DGAT2 (0.58) DGAT2SMN1; SMN2RAB9ANPC1MAPT
SCHEMBL20239325 0.88 DGAT2 (0.45) DGAT2SMN1; SMN2RAB9ANPC1MAPT
SCHEMBL20239322 0.87 DGAT2 (0.44) DGAT2SMN1; SMN2RAB9ANPC1MAPT
SCHEMBL20239132 0.86 DGAT2 (0.46) DGAT2SMN1; SMN2RAB9ANPC1MAPT
SCHEMBL20239141 0.84 DGAT2 (0.42) DGAT2SMN1; SMN2RAB9ANPC1MAPT
SCHEMBL20239333 0.83 DGAT2 (0.56) DGAT2SMN1; SMN2RAB9ANPC1MAPT
SCHEMBL20239175 0.83 DGAT2 (0.42) DGAT2SMN1; SMN2RAB9ANPC1MAPT
SCHEMBL20259074 0.82 DGAT2 (0.41) DGAT2SMN1; SMN2RAB9ANPC1MAPT
SCHEMBL20239162 0.81 P2RX3 (0.39) DGAT2MAPTHPGDGRIN1GRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3298001-B1 DGAT2 INHIBITORS LILLY CO ELI (US) 2020-05-13 EP disclosed
US-10053429-B2 DGAT2 inhibitors ELI LILLY AND COMPANY (US) 2018-08-21 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT DGAT2 1/4885SMN1; SMN2 4828/4885RAB9A 1170/4885
US-10053429-B2 DGAT2 inhibitors DGAT2, DGAT1, LCAT DGAT2 1/4885SMN1; SMN2 4835/4885RAB9A 1119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.